Allelic and phenotypic characterization of CYP2D6 and its encoded P450 cytochrome enzyme in a serie of Spanish type 1 Gaucher disease patients by López de Frutos, L. et al.



























Med  Clin (Barc). 2020;xxx(xx):xxx–xxx
www.elsev ier .es /medic inac l in ica
riginal  article
llelic  and  phenotypic  characterization  of  CYP2D6  and  its  encoded
450  cytochrome  enzyme  in  a  serie  of  Spanish  type  1  Gaucher  disease
atients
aura  López  de  Frutosa,b,∗, Pilar  Alfonsoa,  Carlos  Lahoza,b, Pilar  Irúnc,  Pilar  Giraldob
Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
Fundación para el Estudio y la Terapéutica de la Enfermedad de Gaucher y Otras Lisosomales (FEETEG), Zaragoza, Spain
Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), IIS Aragón, Zaragoza, Spain
 r  t i  c  l  e  i  n  f  o
rticle history:
eceived 22 October 2019
ccepted  30 January 2020
vailable  online xxx
eywords:




a  b  s  t  r  a  c  t
Background:  Cytochrome  p450  is  the main  drug  metabolic  pathway.  CYP2D6  is  a highly  polymorphic  gene
that  encodes  a cytochrome  p450  enzyme  with  three  activity  levels:  null, reduced  and  normal.  Apart  from
another  type  of  mutations  CYP2D6  can  suffer  duplications  and  deletions  of the  entire  gene.  This  is  the
pathway  to  metabolize  one  of the Gaucher  disease  treatments,  whose  dose administration  is  regulated
according  to  the metabolizer  phenotype,  this  being  one  of the administration  limitations.
Objectives: The  aim of  this  paper  is  to evaluate  the  allelic  frequencies  and  the  metabolizer  status  of
Gaucher  type  1 patients  in  the Spanish  population  and  compare  it with  the general  Spanish  population
and  other  Gaucher  disease  groups.
Methods: In this  study,  109  type 1  Gaucher  disease  patients  were  analyzed  with  the xTAG®CYP2D6  kit to
identify  the  CYP2D6  gene  alleles.
Results: We  observed  that  eighty-seven  patients  could  be  classified  as  extensive,  14  as  intermediate,  6 as
poor  and  2 as  ultra-rapid  metabolizers.  The  allelic  duplication  frequency  is 5.5%  and  deletion  is  4.5%.  The
most  common  allele  is  wild-type  and  the  second  is  the  null  *4  allele.  Intermediate  phenotype  frequency
is  higher  than  expected  (p < 0.05).
Conclusions: Our  Spanish  GD  series  shows  an  unexpected  distribution  of  some  alleles  and  phenotypic
metabolizer  status,  in  contrast  to that  previously  reported  in  the Spanish  population.
© 2020  Elsevier  España,  S.L.U.  All  rights  reserved.
Caracterización  alélica  y  fenotípica  del  gen  y  la  enzima  Cyp2d6  en  una  cohorte
de  pacientes  españoles  con  enfermedad  de  Gaucher  tipo  1
alabras clave:
nfermedad de Gaucher tipo 1
en CYP2D6
r  e  s  u  m  e  n
Introducción:  La  superfamilia  citocromo  P450  es  la  principal  vía  de  metabolización  de  fármacos.  Uno  de
los  genes  que la componen,  CYP2D6,  es  altamente  polimórfico  y puede  producir  enzimas  con  3 nivelesPlease cite this article in press as: López de Frutos L, et al. Allelic and phenotypic characterization of CYP2D6 and
its encoded P450 cytochrome enzyme in a serie of Spanish type 1 Gaucher disease patients. Med  Clin (Barc). 2020.
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itocromo P450
YP450  genotipo población española
de  actividad:  nula,  reducida  o  normal.  Además  de  presentar  variantes  puntuales,  este  gen puede  sufrir
duplicidad  o deleción.  CYP2D6  es la principal  vía  de  metabolización  del  último  tratamiento  aprobado
para  la  enfermedad  de  Gaucher,  cuya  administración  y dosificación  depende  del  estado  metabolizador
de  CYP2D6.
Objetivos:  El objetivo  de  este  trabajo  es evaluar  la  frecuencia  alélica  y la distribución  de  fenotipos
metabolizadores  en  una  serie  de  pacientes  españoles  con  enfermedad  de  Gaucher,  y compararla  con
los  datos  publicados  para  población  española  general  y  con  otros  grupos  de  pacientes  de  Gaucher.
Métodos: Se  han  genotipificado  109  pacientes  con enfermedad  de  Gaucher  tipo  1  mediante  el  sistema
xTAG® CYP2D6.
Abbreviations: CYPIID6, cytochrome P450 2D6 enzyme; PharmVar, pharmacogene variation consortium; NM,  normal metabolizer; IM, intermediate metabolizer; PM,  poor
etabolizer; UM,  ultra-rapid metabolizer; AS, activity score; GD, Gaucher disease; GD1, Gaucher disease type 1; Gb1, glucosylceramide; SRT, substrate reduction therapy;
G1,  control group 1; CG2, control group 2.
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E-mail address: llopezdefrutos.uit@gmail.com (L. López de Frutos).
https://doi.org/10.1016/j.medcli.2020.01.032
025-7753/© 2020 Elsevier España, S.L.U. All rights reserved.
ARTICLE IN PRESSG ModelMEDCLI-5143; No. of Pages 6
2 L. López de Frutos et al. / Med Clin (Barc). 2020;xxx(xx):xxx–xxx
Resultados:  Nuestra  población  se  distribuye  en  87 pacientes  con un  fenotipo  metabolizador  normal,
14 intermedios,  6 lentos  y  2 ultrarrápidos.  La  frecuencia  de  la  duplicación  y  deleción  del  gen  es  del 5,5  y
4,5%, respectivamente.  El  alelo  más  común  es la forma  nativa  de  la  proteína  y el  segundo  el  alelo  *4  que
codifica para  una  proteína  inactiva.  La  frecuencia  de  fenotipos  intermedios  es  superior  a  la  esperada  en
población general  (p  < 0,05),  principalmente  a causa  de  un  incremento  en  la frecuencia  de  los  alelos  que
codifican enzimas  con actividad  reducida  (p  <  0,05).
Conclusiones: El  grupo  español  de  pacientes  con  enfermedad  de  Gaucher  muestra  una  distribución  alélica

















































The pharmacodynamics is one of the most important char-
cteristics to know the safety and efficacy of drugs used in
linical practice. It is regulated by its absorption, distribution and
limination process. Drug metabolism includes their oxidation by
ytochrome enzymes.1 Cytochrome P450 superfamily is a group
f oxidases involved in drug metabolism and many other cellu-
ar pathways. There are 18 mammalian cytochrome P450 families,
hich includes 57 human genes, but eleven enzymes are the most
mportant ones for metabolizing drugs, including cytochrome P450
D6 and 3A4.2
The cytochrome P450 2D6 (CYPIID6; Uniprot code P10635) is
n oxidase, member of P450 cytochrome superfamily, involved in
he hepatic clearance of approximately 20% of the most common
rugs, including codeine or paracetamol.1 This enzyme is encoded
y CYP2D6 gene (MIM*608902), it is a highly polymorphic gene
ith 146 alleles according to the pharmacogene variation consor-
ium (PharmVar)3 which presents a differential allele distribution
mong populations.4 Point mutations, deletions, insertions, gene
earrangements, and duplication or deletion of the entire gene are
esponsible for different metabolizer phenotypes. According to the
nzyme activity these fall into four categories: poor metaboliz-
rs (PM) without enzymatic activity; intermediate metabolizers
IM) those with a non-functional allele in combination with a
ormal activity one; extensive or normal metabolizers (NM) with a
ormal activity on both alleles; and ultra-rapid metabolizers (UM)
hose with more than two  functional alleles.5,6
Nowadays this classification is being replaced by an activity
core (AS).7 Those alleles that encode a protein without enzymatic
ctivity obtain a 0 score, those for enzymes with reduced activity
re punctuated with 0.5 and the normal activity encoders obtain 1
oint. The subject alleles sum provided the AS between 0 (two null
lleles) and >3 (subjects with at least three normal alleles). The con-
ensus among experts is clear to define AS = 0 as PM,  AS = 0.5 as IM,
S = 1.5 or 2 as NM and AS > 3 as UM,  but the classification of 1 and
.5 scores is not clear and experts are divided.5
Gaucher disease (GD), the most frequent lysosomal storage
isorder, has been classically subdivided into three clinical phe-
otypes, being type 1 phenotype the most commonly found
GD1; MIM#230800).8 GD is an inherited autosomal recessive
isease, that arises from damaging variants in the GBA1 gene
MIM*606463). The gene includes 11 exons and it is located on
hromosome 1 (1q21-22). On July’18 the professional “Human
ene Mutation Database” included 472 pathogenic variants related
o the disease, but only 4 of them are responsible over 90% of GD1
atients in Ashkenazi Jews and over 50% in non-Jewish patients.8,9
GBA1 gene encodes a lysosomal enzyme named acid
-glucosidase, responsible for glucosylceramide (Gb1) hydrol-Please cite this article in press as: López de Frutos L, et a
its encoded P450 cytochrome enzyme in a serie of Spanish 
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sis. Enzymatic malfunction induces Gb1 accumulation in the
acrophagic mononuclear system cells which are the responsible
or the most frequent or common clinical manifestations of GD:
plenomegaly, hepatomegaly, growth delay and bone disease.8©  2020  Elsevier  España,  S.L.U.  Todos  los  derechos  reservados.
The treatment with recombinant enzyme began in 1991. Nowa-
days it consists of intravenous infusions with a 2-week frequency.
Despite not being curative, it has been proved that it is a safe and
efficient treatment and improves patients life quality.10 Another
treatment option is the substrate reduction therapy (SRT), based
on the inhibition of the enzyme glucosylceramide synthase with
the purpose of reducing the Gb1 synthesis. There are two  drugs
approved for GD and based on SRT, the first approved in 2004 is an
iminosugar (Miglustat, Zavesca®), and its analogy with the gluco-
syl group allows it to inhibit the enzyme by mimetic competition,11
and the second one is a ceramide analogous (Eliglustat, Cerdelga®)
approved in 2015 as GD1 treatment.12
Eliglustat, a tartrate salt analogous to 1-phenyl-2-
decanoylamino-3-morpholino-1-propanol is one of the drugs
metabolized through CYPIID6 enzyme. It is a glucosylceramide
synthase inhibitor that induces a glucosylceramide production
reduction, avoiding its accumulation. It is therefore approved by
the European Union and the United States as a SRT to manage
type 1 Gaucher disease (GD1) patients13 and, it is mandatory to
genotype CYP2D6 to determinate its metabolizing status before
start any treatment with it.14
Despite non-inductors for CYPIID6 have been described, it is
necessary to identify functional differences in the cytochrome
activity to avoid clinical issues due to pharmacological
interactions,1,15 as well as avoid high drug doses such that
the patient cannot metabolize properly. The aim of this project
is to analyze the allelic status of CYP2D6 and the corresponding
phenotype on CYPIID6 on a Spanish GD1 patients’ population.
Methods
Patients
We  have studied 109 patients (GD-S group), older than 18 years
of age, with confirmed enzymatic and genetic diagnosis of GD, and
a clinical classification for type 1 included in the Spanish Gaucher
disease Registry. The study design was approved by the institu-
tional board of FEETEG foundation. All individuals were provided
with the written informed consent and the study was conducted in
accordance with the principles stated in the Declaration of Helsinki
- Ethical Principles for Medical Research Involving Human Sub-
jects, Helsinki, Finland, 1964, and as amended in Fortaleza, Brazil,
2013. The exclusion criteria were the inclusion on the clinical trial
ENCORE.
GBA1 sequencing
The  GBA1 gene was  amplified according to the previouslyl. Allelic and phenotypic characterization of CYP2D6 and
type 1 Gaucher disease patients. Med  Clin (Barc). 2020.
published.16 To summarize it, a long-chain PCR using specific
primers of the functional GBA1 gene and subsequent nested PCR
of each exonic region were performed. Products were sequenced
by capillary electrophoresis and analyzed with the Variant Report
 IN PRESSG ModelM















































GBA1  genotypes in our sample. GBA1 genotype frequency. Compound heterozygous
with  the variants NM 000157.3:c.1226A>G and c.1448T>C is the most common, fol-
low by the homozygous state for the variant NM 000157.3:c.1226A>G. Other 30
variants have been found on combination with the c.1226A>G, half of it only has
been observed in one patient.
TOTAL (109) Frequency
(%)
GBA1 damaging variants (NM 000157)
[c.1226A>G + c.1448T>C] 38 34.86%
[c.1226A>G + c.1226A>G] 12 11.01%
[c.1226A>G + c.84dupG] 5 4.59%
[c.1226A>G + c.1263 1317del55] 3 2.75%
[c.1226A>G + c.517A>C] 3 2.75%
[c.1226A>G + c.1093G>A + c.679 680delAAinsTC] 3 2.75%
[c.1226A>G + c.700G>T] 3 2.75%
[c.1226A>G + c.721G>A] 3 2.75%
[c.1226A>G + c.1601G>A] 3 2.75%
[c.1226A>G + c.1289C>T] 3 2.75%
[c.1226A>G + c.107G>A] 3 2.75%
[c.1226A>G + c.1439 1445del7] 2 1.83%
[c.1226A>G + c.1090G>T] 2 1.83%
[c.1226A>G + c.455G>A] 2 1.83%
[c.1226A>G + c.256C>T] 2 1.83%
[c.1226A>G + c.604C>T] 2 1.83%
[c.1226A>G + RecNciI] 2 1.83%ARTICLEEDCLI-5143; No. of Pages 6
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.1 software. Results were compared to the reference sequence
vailable in the GeneBank database (NG 009783.1).
YP2D6 genotyping
The allele identification of the CYP2D6 gene (GeneBank
atabase  reference: NG 008376.3) was done according to the
TAG®CYP2D6v3 (Luminex Corporation, Texas, USA) manufacturer
nstructions.
This kit analyzes 19 genetic variants and the presence of genetic
eletions or duplications that allowed us to identify 17 alleles and
stablish a metabolizer phenotype for all evaluated patient.
Briefly,  DNA was first isolated and purified from whole blood
sing a commercial extraction kit, and according to the manu-
acturer instructions. A UV 260/280 ratio purity of at least 1.5 is
ecessary to perform the genotyping assay. Gene duplication and
9 SNPs were amplified by multiplex PCR and cleaned by enzymatic
urification. Multiplex allele-specific primer extension was  then
erformed, followed by a bead hybridization. Finally, a reporter
olecule was added, washed and analyzed on xMAPTM equipment.
All reactions included a negative control and a control sample
or each metabolizer status. All patients with gene duplication were
nalyzed twice.
YP2D6 genotype–phenotype correlation
The correlation between genotype and phenotype has been
ade by the allelic correlation, establishing 4 activity groups: NM,
M,  IM and UM phenotypes and, according to the activity score (AS)
ublished by Gaedigk in 2008.6,7
Each allele has an assigned score between 0 and 2, and the sum
f both alleles provides an AS that allow us to classify the patients
etween 0 predicting poor metabolizers, and >2 predicting ultra-
apid metabolizers.
The  correlation between the AS and the classical phenotype
ssignation has been done defining poor metabolizer as those with
S = 0, intermediate metabolizer with AS = 0.5, normal metabolizer
s those with AS between 1 and 2 and ultra-rapid metabolizers as
hose with activity score > 3.
ontrol  data analysis
Three  control dataset were obtained from the literature.
The first one (Control group 1; CG1) was  obtained from
he Spanish reports included on the Pharmgkb Database
https://www.pharmgkb.org/page/cyp2d6RefMaterials). This
atabase includes 11 papers published between 2004 and 2017,
ut only 5 of them analyze all the alleles, so only these have been
onsidered to prepare our control population dataset.17–21
The second one (Control group 2; CG2) was obtained from one
f the most recent papers about the genotypes and phenotypes
YP2D6 frequencies. This report includes 6060 healthy subjects,
537 of them Iberian (1081 Spanish population).22 As this report
oes not analyze *9 allele and it is characterized by one specific
ariant, its general frequency has been obtained from the Spanish
ariant Server.23
The third group (Control group 3; ENCORE) was  obtained from
linical trial ENCORE published data.24 This group only includes
etabolizer status information because allelic and AS information
s not available.Please cite this article in press as: López de Frutos L, et a
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tatistical analysis
The  AS, metabolizer phenotype and allele frequency variabil-
ty with the control groups were analyzed by chi-square test,15 × [c.1226A>G + + Other] 15 13.76%
[Other + Other] 3 2.75%
considering statistically significant those p-values < 0.05. All statis-
tics were analyzed by IBM SPSS statistics v22 software.
Results
Genotype and phenotype description on GD-S patients
We analyzed 109 subjects, with a gender proportion of 1:1 (55
females and 54 males). The most common damaging variant of
GBA1 is NM 000157:c.1226A>G (NP 000148:p.Asn409Ser), it was
found on 53.0% of patients, followed by NM 000157:c.1448T>C
(NP  000148:p.Leu483Pro) with a frequency of 18.0%. All other
found variants presented a low frequency between 2.8 and 0.5%
(Table 1).
All  patients were classified according to their CYPIID6
metabolizer status, 87 are NM,  14 IM,  6 PM and only 2 are UM
(Fig. 1A) and according to their activity score: 6 are AS = 0, 13 are
AS = 0.5, 25 are AS = 1, 18 are AS = 1.5, 45 subjects are AS = 2 and
only 2 patients have an AS > 2 (Fig. 1B). There are no significant
differences in phenotype or allele distributions among patients
depending on their gender. No relationship has been observed
between GBA1 and CYP2D6 genotypes (p > 0.05).
Six subjects have an allele duplication, but in 3 cases it is com-
bined with *4 allele (it codifies for a null enzyme) and the other case
is in combination with alleles that encode enzymes with reduced
activity, so they cannot be considered UM despite the duplication.
A total of 5 subjects show a deletion (carriers for *5 allele).
The  most frequent genetic variant is NG 008376.3:g.8381G>C
(NM  000106.5:c.1547G>C), the minor allele frequency for this
variant on this study is 51.8% and it is not related to a metabolizer
phenotype.
The most frequent allele in our project is the wild-type form
(39.00%), followed by the null *4 allele (19.0%) and the normal func-
tion *2 allele (17.0%). The *7, *8, *11, *15 alleles, that encode for
non-functional proteins and *29 which encodes a reduced activity
protein, are not present in our population (Fig. 2).l. Allelic and phenotypic characterization of CYP2D6 and
type 1 Gaucher disease patients. Med  Clin (Barc). 2020.
At  least one allele encoding for a non-functional protein is found
in 53 subjects (48.6%) and at least one for a reduced function protein
in 15 patients (13.8%).
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Fig. 1. Metabolizer phenotype distribution. (A) Observed frequency for each metabolizer phenotype in the studied population. EM = 87 patients; IM = 14 patients; PM = 6
patients  and UM = 2 patients. The distribution is the expected according with the literature for the Spanish population. (B) Observed activity score frequency in the studied
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Fig. 2. Allele frequency distribution of CYP2D6 in 109 GD1 patients. Observed allele distrib
grey,  the reduced activity alleles are in grey and the null activity encoder alleles are soft g
they  are not represented on the figure.
Table 2
CYP2D6 variants distribution. Frequency of each analyzed variant on CYP2D6 in our
population. Not all variants define an allele and some alleles need more than one
variant to be defined.
Allele Variant TOTAL (109) Frequency (%)
CYP2D6 genetic variants (NM 000106.5)
Duplication 6 2.75%
*5 Deletion 5 2.29%
*2 c.-1584C>G 44 20.18%
*35 c.31G>A 8 3.67%
*10 c.100C>T 47 21.56%
c.124G>A  0 0.00%
*15 c.137 138insT 0 0.00%
*11 c.181-1G>C 0 0.00%
*17 c.320C>T 2 0.92%
*29 c.406G>A 0 0.00%
c.408G>C  112 51.38%
*6 c.454delT 3 1.38%
*8 c.504C>T 2 0.92%
*4 c.506-1G>A 42 19.27%
*3 c.775delA 2 0.92%
*9 c.841 843delAAG 10 4.59%
*2 c.886C>A 66 30.28%
*7 c.971A>C 0 0.00%








*29 c.1012G>A 0 0.00%
*2 c.1457G>C 113 51.83%
The most common genetic variant related with a non-functional
rotein is NM 000106.5:c.506-1G>A which defines the *4 allele
ounded in 19.00% of cases, while the most common for a reduced
unctional protein is NM 0001065:c.841delAAG, defining the *9
llele founded in 5.00% of cases (Table 2).
omparison with control groupsPlease cite this article in press as: López de Frutos L, et a
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The source used to design CG1 and ENCORE datasets does not
llow us to classify these groups according to the activity score, so
e are not able to make this comparison.ution in the studied population. Alleles that encodes for normal activity are in dark
rey coloured. The *7, *8, *11, *15 and *29 alleles are not found in our population, so
The  comparison study of the distribution of the metabo-
lizer phenotype between our GD-S population and the CG1
showed significant statistically differences on the frequency
of the IM phenotype (p-value = 0.028), being this phenotype
much more common in our GD-S population than in the CG1
(12.8% vs 7.2%).
The  allele frequencies also showed an alteration on the distri-
bution, the frequency of *2 allele is lower than expected (16.1%
vs 27.8%), the opposite was found for the *35 allele which is
higher than expected (3.7% vs 1.7%). That differences are sta-
tistically significances (p-value = 0.001 and 0.044, respectively).
In addition, alleles that encodes for a protein with a reduced
function shown an unexpected distribution being the frequency
of *6 and *41 alleles on GD-S patients higher than in the
CG1 (1.4% vs 0.3% and 8.3% vs 4.1% respectively). Those differ-
ences are, again, statistically significant (p-value = 0.045 and 0.044,
respectively).
When GD patients are compared with the CG2 we obtain
similar results. In this case we  could analyze the activity score
frequency, and we observed than AS = 0.5 showed statistically sig-
nificant differences between both groups (p-value = 0.003), being
its frequency double on GD patients than in the control group
(11.93% vs 5.56%). As expected, due to the AS distribution, the fre-
quency of the IM phenotype was  higher on GD patients than in
CG2 (12.84% vs 5.56%; p-value = 0.001). On this group the allelic
distribution showed statistically significant differences in relation
with the reduced activity enzyme encoders *6 and *9 alleles, being
those higher on GD patients than on CG2 (1.4% and 4.6% vs 0.6%
and 1.5%, respectively) with p-values = 0.045 and 0.001, respec-
tively.
Comparison with other GD population, the worldwide popula-
tion included on the ENCORE clinical trial, do not show statisticallyl. Allelic and phenotypic characterization of CYP2D6 and
type 1 Gaucher disease patients. Med  Clin (Barc). 2020.
significant differences between the metabolizer phenotypes dis-
tribution and our GD-S group (p > 0.05) but shows it when
compared with IM frequency in general Spanish population (CG1
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iscussion
This is the first paper describing the genotypic and phenotypic
requency for CYP2D6 and CYPIID6 on Gaucher disease population,
reviously only phenotypic frequencies has been reported in one
aper.24
The metabolizer phenotype frequency on this study showed
ifferences with the previously published data for Spanish and
berian population, observing and increased frequency on IM (12.8%
s 7.2% or 5.6%, respectively) or the equivalent AS = 0.5 (11.9% vs
.6%). Differences on UM frequencies are not statistically signifi-
ant (p-value > 0.05) but show a tendency to be lower in the GD-S
opulation than the Spanish or Iberian populations used as control
roups (1.8% vs 3.3% and 5.0%, respectively).22,25
The analysis of allelic frequencies of the different groups
ccording to the encoded protein activity does not match with
ata recently published, with a decreased frequency for normal
ncoders alleles and an increased one for the reducer encoders
p < 0.01). A possible explanation is the reduced frequency of *2
llele in our population, but we do not have any explanation
o justify this reduction. This can be important due to the use
f concomitant therapies with drugs metabolized by the same
ytochrome pathway, as antihistaminic or antiarrhythmic drugs,
s well as substances capable of inhibiting this metabolic pathway,
hich can affect harder than in other populations, raising the drug
oxicity. Usually, drug administration does not take in consider-
tion the genotype or regroup the four metabolizer phenotypes
n three groups: PM with reduced doses, UM not available for the
reatment and IM+NM with the standard doses. But it is necessary
o consider the huge range of CYP2D6 activities included on the
ast group, with an AS range from 0.5 to 2. The interpretation of
YP2D6 genotypes beyond the metabolizer phenotype extrapola-
ion is important to understand possible drug-drug interactions
nd to understand and, finally prevent, adverse reactions. So, it
s necessary to increase the information about patients’ response
o CYP2D6 metabolized therapies with every-day clinical practice
eports to elucidate the importance of our results.
A tendency, although not statistically significant, has been
bserved on the allele duplications frequency. This is higher than
reviously published.26 However, due to the higher frequency of
lleles that encode null or reduced functional proteins, this increase
s not reflected on the UM frequency.
Our results were compared with the recently published data
or Ashkenazi Jews, a population with a high frequency of damag-
ng variants on GBA1. It is remarkably the difference between the
5 allele frequency (2.3% vs 1.1%; p = 0.001), as well as the higher
requency in our population for *6 and *9 alleles (1.4% vs 0.8%;
 = 0.028 and 4.6% vs 0.4%; p = 0.001 respectively)27 finding a higher
ercentage of alleles that encodes for a null o reduced activity pro-
ein in our population than in the Jewish population. This is the
ame difference that we found with the published Spanish popula-
ion. In contrast with these results, is remarkable the concordance
etween our results in GD-S population and the other published GD
atient’s data (ENCORE clinical trial), encouraging our believe that
here is any relation between GD disease and alleles that encodes
or reduced activities CYP2D6 enzymes. Despite this, no correlation
etween GBA1 damaging variants distribution and CYP2D6 geno-
ypes were found in our study as expected due to the genomic
ocation for both genes.
onclusionsPlease cite this article in press as: López de Frutos L, et a
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In  conclusion, this is the first publication that describes the
enotype profile of CYP2D6 in Spanish GD population and shows




comparing with general Spanish population. As these differences
that were not previously observed in comparison with GD patients
on ENCORE clinical trial (data not shown),24 it is necessary to
increase the analyzed series and perform more studies to confirm
a correlation between GD and GYP2D6 genotype.
We can confirm the independence between allele frequency and
gender or GBA1 genotype, but we  found some disagreements with
previously published data in relation to the second most frequent
allele or the allele duplication frequency as well as the frequency
for reduced activity encoder’s alleles. This is a relevant informa-
tion to consider due to the importance of this cytochrome on drug
metabolism and to prevent the drug interferences, knowing that
the risk of adverse effects by them is higher on patients with the
lowest CYPIID6 activity.
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